Company: HRTX
Filing Date: 2025-04-30
Form Type: DEF 14A
Source: 0000950170-25-060882
Chunk: 52

Company: HERON THERAPEUTICS, INC. /DE/
Filing Date: 2025-04-30
Form: DEF 14A
Chunk 52
---
296,125 |
|                |     | Benefits Continuation                                         |     | $                     |    27,334 |     | $           |    27,334 |
|                |     | Value of unvested stock options that would be accelerated (1) |     | $                     |    52,500 |     | $           |   921,250 |
|                |     | Value of unvested stock awards that would be accelerated      |     | $                     |    42,835 |     | $           |   134,435 |
|                |     | Total                                                         |     | $                     | 1,011,044 |     | $           | 1,971,394 |

(1) Per the applicable agreement with the Company, performance based options will vest upon a change in control based on the per share consideration received by the Company in connection with such change in control, such that a termination is not required. The corresponding value is included in the "Termination due to CIC" column. In addition, as disclosed above, the Collard Agreement provides that Mr. Collard’s initial time-based option to purchase 3,000,000 shares of the Company’s common stock, and his initial time-based restricted stock unit award covering 250,000 shares of the Company’s common stock, both of which were granted in 2023, will vest as to an additional 6 months of service if his employment as Chief Executive Officer is terminated and he remains a member of the Board following such termination. Assuming such a termination occurred on December 31, 2024, the value of such acceleration is $0 with respect to such option (since the option is "underwater") and $95,625 with respect to such restricted stock unit award.

38

Equity Compensation Plan Information We maintain the following equity compensation plans under which our equity securities that have been issued or are authorized for issuance to our employees and/or directors. The following table presents information about these plans as of December 31, 2024.

| Plan Category                                              |     | Number of Securities to be Issued Upon Exercise of Outstanding Options, Warrants and Rights |            |     |    |     | Weighted Average Exercise Price of Outstanding Options, Warrants and Rights |      |     |    |     | Number of Securities Remaining Available for Future Issuance Under Equity Compensation  Plans (Excluding Securities Reflected in Column 2) |            |     |    |
|:-----------------------------------------------------------|